Welcome to our dedicated page for Lifeway Food SEC filings (Ticker: LWAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Lifeway Foods, Inc. (NASDAQ: LWAY), an Illinois-based manufacturer of probiotic, cultured and fermented dairy foods. Through these filings, investors can review how the company reports financial performance, governance changes and key agreements that affect LWAY common stock.
Recent Form 8-K current reports document a range of material events. One 8-K dated November 12, 2025 furnishes five-year financial projections that Lifeway provided to Danone North America PBC during due diligence for a potential transaction, including net sales, gross profit, operating income, Adjusted EBITDA, capital expenditures and free cash flow. Other 8-Ks disclose estimated unaudited net sales for a fiscal quarter, the execution of a Cooperation Agreement with Danone, the appointment and resignation of directors, and the scheduling of annual shareholder meetings.
Filings also describe governance and rights arrangements. An 8-K dated October 29, 2025 outlines Amendment No. 1 to the Shareholder Rights Agreement, extending the expiration of a shareholder rights plan and explaining the board’s rationale related to concentrated share ownership and potential accumulation of control without a premium. Another 8-K filed September 30, 2025 details the Cooperation Agreement with Danone, including board refreshment, voting commitments and registration rights for Danone’s holdings.
On Stock Titan, Lifeway’s SEC filings are updated in step with the EDGAR system and paired with AI-powered summaries that explain the significance of each document in clear language. Users can quickly scan 8-K disclosures for governance and transaction developments, and refer to annual and quarterly reports when available for a broader view of Lifeway’s financial condition and risk factors, without having to interpret every technical section themselves.
Divisadero-related investors report collective ownership of 861,369 shares of Lifeway Foods common stock, representing
Lifeway Foods, Inc. (LWAY) notice reports a proposed sale of 15,000 common shares through RBC Capital Markets with an aggregate market value of
Juan Carlos Dalto, a director of Lifeway Foods, Inc. (LWAY), reported changes in his holdings tied to director compensation and previously granted awards. The filing shows a disposition of 4,751 shares of common stock and the acquisition (by vesting or deferral) of derivative awards that translate to 2,815 shares of common stock: 1,600, 3,101, and 2,710 RSU tranches (with portions deferred or contingent on continued service) and 541 shares of phantom stock acquired via deferral of cash board fees. Many RSUs are vested but settlement has been deferred under the company’s Non-Employee Director Equity and Deferred Compensation Plan; deferred awards become payable when the reporting person ceases to serve as a director. Some RSU tranches remain time‑vesting and are contingent on continued board service.
Lifeway Foods insider intends to sell 26,847 common shares (approximately $697,586.60 in aggregate market value) through Merrill Lynch on NASDAQ around 10/01/2025. The filing shows all 26,847 shares were acquired as compensation from the issuer on multiple dates between 07/28/2005 and 07/01/2025. The total number of outstanding shares is listed as 15,226,520, and the transaction will be executed via broker-dealer Merrill Lynch at 75 Rockefeller Plaza, New York.
Danone holds 3,454,756 shares of Lifeway Foods, representing 22.7% of the outstanding common stock based on 15,226,520 shares. This filing is Amendment No. 11 to Danone's long‑standing Schedule 13D and reports a Letter Agreement dated September 30, 2025 between Danone North America PBC and Lifeway. The Letter Agreement is designed to give Danone additional optionality to sell its stake and, among other things, requires Lifeway to maintain a shelf registration to facilitate potential sales, contemplates appointment of three independent directors within 30 days and a fourth within 45 days acceptable to Danone, contemplates an independent board chair, contains voting commitments by Danone subject to exceptions, seeks a joint effort to stay pending litigation, and includes mutual non‑disparagement and Stockholders' Agreement compliance provisions.
Lifeway Foods, Inc. disclosed changes to its agreements with Danone that limit Danone's involvement in corporate governance and certain transfer restrictions. Danone will not need to consent for the company to grant market‑term equity compensation to management (excluding JS, her immediate family and affiliates) provided the Compensation Committee—with a majority of New Independent Directors—approves the grants. Danone also waived its rights to board and committee representation and agreed to waive rights of first refusal on certain monthly sales by ES, LS and JS of up to 100,000 shares each, subject to those parties waiving claims related to shares held by Michael Smolyansky's estate. Danone's remaining Stockholders' Agreement rights (other than registration and books-and-records rights) will end once Danone and affiliates hold fewer than 761,438 shares (adjusted for recapitalizations).
Edward Smolyansky, a director of Lifeway Foods, Inc. (LWAY), reported open-market sales of common stock on 09/23/2025 and 09/24/2025. He sold 6,357 shares on 09/23/2025 at a weighted average price of $26.53 and 10,000 shares on 09/24/2025 at a weighted average price of $26.69, reducing his direct holdings to 1,235,285 shares. The filing also discloses multiple indirect holdings: 75,000 shares held by a family foundation, 1,233,333 shares in a trust for which he is trustee, 100,000 shares owned by his son (disclaimed), and 500,000 shares held by Smolyansky Holding LLC (partially disclaimed). The form is signed and dated 09/25/2025.